John G. Gribben is a Professor of Experimental Cancer Medicine, Director of the Experimental Cancer Medicine Centre and Director of Stem Cell Transplantation at Saint Bartholomew's Hospital, Queen Mary's School of Medicine, University of London.
After obtaining his medical degree, he spent 5 years as a Research Fellow in Haematology at University College London, where he was a Leukaemia Research Fund Fellow and recipient of a Welcome Trust Fellowship Award. In 1989, he received a Fogarty International Fellowship to continue post-doctoral training at the Dana-Farber Cancer Institute, Harvard Medical School. In 1992, he was appointed to the Faculty at Harvard Medical School, where he remained an Associate Professor of Medicine and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, until moving to London in October 2004. He is also a founding member of the CLL Research Consortium.
An internationally recognized translational cancer researcher, John Gribben is an author of more than 200 manuscripts and book chapters. His primary research interests include the immunotherapy of cancer (including stem-cell transplantation), the identification of B-cell-tumour antigens, and the detection and treatment of minimal residual disease in leukaemia and lymphoma. He is also an Associate Editor of Blood.
Dr. Gribben holds the following fellowships and memberships:
Fellow of the Academy of Medical Sciences
Fellow of the Royal College of Physicians
Fellow of the Royal College of Pathologists
Member of the American Society for Clinical Investigation
Barts Cancer Center of Excellence/The London School of Medicine